Is a libido change a side effect of GLP-1s?
No — not a labeled one. We checked the current FDA prescribing information, and neither decreased libido, sexual dysfunction, nor erectile dysfunction appears in the adverse-reactions section for Ozempic, Wegovy, Mounjaro, or Zepbound. That does not mean nobody ever notices a change; it means the trials did not identify a consistent drug effect on sexual desire. When a change happens, the most likely driver is the weight loss and the hormonal shifts that come with it — not the molecule acting directly on libido.
Men: weight loss, testosterone, and erectile function
This is where the evidence is strongest, and it is an indirect story. Obesity commonly causes a reversible low-testosterone state — extra fat tissue converts testosterone to estrogen and disrupts the hormonal axis. Losing visceral fat and improving insulin sensitivity reverses much of that, and testosterone rises.
- A controlled pilot of tirzepatide in men with obesity and low testosterone found significant rises in testosterone and improved erectile-function (IIEF-5) scores at two months.
- A small semaglutide trial in similar men raised testosterone and improved sexual-desire scores, though testosterone-replacement therapy improved erectile function more broadly.
The honest caveat: these are small, short, early studies, and the benefit is attributed mainly to weight loss and metabolic improvement, not a proven direct drug action. They are a promising signal, not a settled conclusion.
The mixed evidence on desire itself
Set against the testosterone story, the data on the drug directly changing desire pull in different directions:
- No effect: a randomized trial of dulaglutide in healthy men found no significant change in sexual desire, testosterone, or gonadotropins after four weeks.
- Possibly lower: some theoretical papers propose GLP-1s could dampen desire through serotonin pathways, similar to how some antidepressants do — but these are hypotheses, not outcome trials.
- More ED in one dataset: an observational study reported a higher rate of new erectile dysfunction in non-diabetic men on semaglutide — but observational data cannot separate the drug from the underlying health picture.
- Pharmacovigilance: spontaneous reports of decreased libido exist, but the reporting analyses describe the association as weak with a low absolute risk.
Because these conflict and it is not a labeled effect, the accurate summary is: the drug's direct effect on libido is unproven and probably small in either direction, and any big change you notice is more likely tied to weight, mood, or another cause.
Women
There is little clinical data on female libido and GLP-1s specifically. In general, weight loss and better metabolic health can improve body image, energy, and sexual function for some women, while the same theoretical serotonin mechanism could reduce desire for others. The net effect is simply not established — an honest “we don't really know yet.” If you are noticing a change, it is worth raising with your clinician rather than assuming the medication is the cause.
One thing worth acting on: new or sudden erectile dysfunction can be an early warning sign of heart or blood-vessel disease, or a hormonal problem — not something to write off as a drug side effect. Get it checked. This page is general information, not medical advice.